Business Context and Reporting Period
This Form 6-K filing by Zai Lab Ltd. covers the month of November 2018. The report details a strategic collaboration entered into on November 29, 2018, between Zai Lab (Shanghai) Co., Ltd. and MacroGenics, Inc.
Key Financial Metrics
The filing does not provide standard financial statements such as revenue, profit, cash flow, margins, or debt levels for the period. The primary financial data disclosed relates to the terms of the new Collaboration Agreement:
- Up-Front Payment: $25.0 million non-refundable license fee payable to MacroGenics.
- Milestone Payments: Potential development and regulatory-based payments of up to $140.0 million.
- Royalties: Tiered royalties ranging from mid-teens to 20% for margetuximab, mid-teens for MGD013, and 10% for the TRIDENT molecule on net sales within the Territory.
Material Changes
The material change reported is the execution of the Collaboration Agreement granting Zai Lab exclusive regional development and commercialization rights in China, Hong Kong, Macau, and Taiwan for:
- Margetuximab
- MGD013
- An undisclosed multi-specific TRIDENT molecule (in preclinical development)
The parties intend to initiate a global study using combination regimens containing margetuximab to target gastric cancer.
Outlook, Risks, and Contingencies
Agreement Terms: The agreement is effective from November 29, 2018. Zai may terminate for convenience after November 29, 2020. MacroGenics may terminate if major safety issues arise prior to the first commercial sale and global development is discontinued.
Risks and Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements. Key risks identified include:
- Ability to obtain additional future funding.
- Results of clinical and pre-clinical development.
- Regulatory approval timing and content.
- Ability to generate revenue from drug candidates.
Investor Verification Checklist
- Verify the impact of the $25.0 million upfront payment on Zai Lab's current cash position and liquidity.
- Confirm the specific clinical trial timelines for the global study on margetuximab in gastric cancer.
- Review the full text of the Collaboration Agreement (to be filed as an exhibit to the next periodic report) for detailed milestone definitions.
- Assess the regulatory pathway for margetuximab and MGD013 in the Greater China region.